The Management of Severe Sepsis and Septic Shock

Infectious Disease Clinics of North America

Volumn 23, Issue 3, 2009, Pages 485-501

  Morrell, Matthew R ^a   Micek, Scott T ^b   Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Biomarkers; Empiric antibiotics; Goal directed therapy; Septic shock; Severe sepsis; Vasoactive agents

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CARBAPENEM; CEFEPIME; CORTICOSTEROID; DEXAMETHASONE; DOBUTAMINE; DOPAMINE; DROTRECOGIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; HYPERTENSIVE AGENT; INOTROPIC AGENT; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NORADRENALIN; PHENYLEPHRINE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PROTON PUMP INHIBITOR; RECOMBINANT ERYTHROPOIETIN; VASOACTIVE AGENT; VASOPRESSIN;

ACUTE LUNG INJURY; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIUM CULTURE; BLOOD PRESSURE MONITORING; BLOOD TRANSFUSION; CATHETERIZATION; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENTERIC FEEDING; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMIC MONITORING; HIGH RISK POPULATION; HUMAN; HYPERINSULINEMIA; INFECTION CONTROL; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NUTRITIONAL DEFICIENCY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PARENTERAL NUTRITION; POSITIVE END EXPIRATORY PRESSURE; RESPIRATORY FAILURE; RESUSCITATION; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; STRESS ULCER;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CATHETERIZATION, CENTRAL VENOUS; CRITICAL ILLNESS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RESPIRATION, ARTIFICIAL; SEPSIS; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 68049146030     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.04.002     Document Type: Review

References (82)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 7 (2001) 1303-1310
2. Sasse K.C., Nauenberg E., Long A., et al. Long-term survival after intensive care unit admission with sepsis. Crit Care Med 23 6 (1995) 1040-1047
3. Annane D., Aegerter P., Jars-Guincestre M.C., et al. Current epidemiology of septic shock: the CUB-Réa network. Am J Respir Crit Care Med 168 2 (2003) 165-172
4. Kung H.C., Hoyert D.L., Xu J., et al. Deaths: final data for 2005. Natl Vital Stat Rep 56 10 (2008) 1-120
5. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31 4 (2003) 1250-1256
6. Annane D., Bellissant E., and Cavaillon J.M. Septic shock. Lancet 365 9453 (2005) 63-78
7. Lin M.T., and Albertson T.E. Genomic polymorphisms in sepsis. Crit Care Med 32 2 (2004) 569-579
8. Alberti C., Brun-Buisson C., Burchardi H., et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28 2 (2002) 108-121
9. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 2 (2003) 138-150
10. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 19 (2001) 1368-1377
11. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 1 (2008) 296-327
12. Nguyen H.B., Corbett S.W., Steele R., et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med 35 4 (2007) 1105-1112
13. Bendjelid K., and Romand J.A. Fluid responsiveness in mechanically ventilated patients: a review of indices used in intensive care. Intensive Care Med 29 3 (2003) 352-360
14. Finfer S., Bellomo R., Boyce N., et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350 22 (2004) 2247-2256
15. Schortgen F., Lacherade J.C., Bruneel F., et al. Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomized study. Lancet 357 9260 (2001) 911-916
16. De Jonge E., and Levi M. Effects of different plasma substitues on blood coagulation: a comparative review. Crit Care Med 29 6 (2001) 1261-1267
17. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49 9 (2005) 3640-3645
18. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 1 (2000) 146-155
19. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 2 (1999) 263-274
20. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 6 (2006) 1589-1596
21. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2000. Am J Infect Control 32 8 (2004) 470-485
22. Rosenthal V.D., Maki D.G., Mehta A., et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 36 9 (2008) 627-637
23. Labelle A.J., Micek S.T., Roubinian N., et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 36 11 (2008) 2967-2972
24. Micek S.T., Lloyd A.E., Ritchie D.J., et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 4 (2005) 1306-1311
25. Tam V.H., Gamez E.A., Weston J.S., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of resistance breakpoint. Clin Infect Dis 46 6 (2008) 862-867
26. Boselli E., Breilh D., Rimmelé T., et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 36 5 (2008) 1500-1506
27. Dellit T.H., Owens R.C., McGowan Jr. J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44 2 (2007) 159-177
28. Micek S.T., Roubinian N., Heuring T., et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 34 11 (2006) 2707-2713
29. Wiener R.S., and Welch H.G. Trends in the use of pulmonary artery catheter in the United States, 1993-2004. JAMA 298 4 (2007) 423-429
30. Osman D., Ridel C., Ray P., et al. Cardiac filling pressure are not appropriate to predict hemodynamic response to volume challenge. Crit Care Med 35 1 (2007) 64-68
31. LeDoux D., Astiz M.E., Carpati C.M., et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 28 8 (2000) 2729-2732
32. Müllner M., Urbanek B., Havel C., et al. Vasopressors for shock. Cochrane Database Syst Rev 3 (2004) CD003709
33. Hollenberg S.M., Ahrens T.S., Annane D., et al. Practice parameters for hemodynamic support of sepsis in adult patients. Crit Care Med 32 9 (2004) 1928-1948
34. Bellomo R., Chapman M., Finfer S., et al. Low dose dopamine in patients with early renal dysfunction: a placebo-controlled randomized trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356 9248 (2000) 2139-2143
35. Regnier B., Rapin M., Gory G., et al. Haemodynamic effects of dopamine in septic shock. Intensive Care Med 3 2 (1977) 47-53
36. De Backer D., Creteur J., Silva E., et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best?. Crit Care Med 31 6 (2003) 1659-1667
37. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 5 (1997) 1122-1125
38. Patel B.M., Chittock D.R., Russell J.A., et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96 3 (2002) 576-582
39. Holmes C.L., Walley K.R., Chittock D.R., et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27 8 (2001) 1416-1421
40. Russell J.A., Walley K.R., Singer J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358 9 (2008) 877-887
41. Marshall J.C., Maier R.V., Jimenez M., et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 32 11 Suppl (2004) S513-S526
42. Jimenez M.F., and Marshall J.C. Source control in the management of sepsis. Intensive Care Med 27 Suppl 1 (2001) S49-S62
43. Evans A., and Winslow B.H. Oxygen saturation and hemodynamic response in critically ill mechanically ventilated adults during intra-hospital transport. Am J Crit Care 4 2 (1995) 106-111
44. Sprung C.L., Caralis P.V., Marcial E.H., et al. The effect of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 311 18 (1984) 1137-1143
45. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 317 11 (1987) 659-665
46. Briegel J., Forst H., Haller M., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27 4 (1999) 723-732
47. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 7 (2002) 862-871
48. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 2 (2008) 111-124
49. Marik P.E., Pastores S.M., Annane D., et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 36 6 (2008) 1937-1949
50. Reincke M., Allolio B., Würth G., et al. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotrophin-releasing hormone. J Clin Endocrinol Metab 77 1 (1993) 151-156
51. Lorente J.A., García-Frade L.J., Landín L., et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103 5 (1993) 1536-1542
52. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 10 (2001) 699-709
53. Vincent J.L., Bernard G.R., Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 10 (2005) 2266-2277
54. Abraham E., Laterre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 13 (2005) 1332-1341
55. Gao F., Gao E., Yue T.L., et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105 12 (2002) 1497-1502
56. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 19 (2001) 1359-1367
57. Van den Berghe G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 5 (2006) 449-461
58. Brunkhorst F.M., Engel C., Bloos F., et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358 2 (2008) 125-139
59. Corwin H.L., Gettinger A., Rodriguez R.M., et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 27 (1999) 2346-2350
60. Hébert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized controlled trial of transfusion requirements in critical care. N Engl J Med 340 6 (1999) 409-417
61. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342 18 (2000) 1301-1308
62. Ranieri V.M., Suter P.M., Tortorella C., et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 282 (1999) 54-61
63. Gattinoni L., Caironi P., Cressoni M., et al. Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med 354 17 (2006) 1775-1786
64. Nguyen N.Q., Fraser R.J., Bryant L.K., et al. Diminished functional association between proximal and distal gastric motility in critically ill patients. Intensive Care Med 34 (2008) 1246-1255
65. Marik P.E., and Zaloga G.P. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 29 12 (2001) 2264-2270
66. Roberts S.R., Kennerly D.A., Keane D., et al. Nutrition support in the intensive care unit. Adequacy, timeliness and outcomes. Crit Care Nurse 23 6 (2003) 49-57
67. Halkin H., Goldberg J., Modan M., et al. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 96 5 (1982) 561-565
68. Pingleton S.K., Bone R.C., Pingleton W.W., et al. Prevention of pulmonary emboli in a respiratory intensive care unit: efficacy of low-dose heparin. Chest 79 6 (1981) 647-650
69. Cook D.J., Fuller H.D., Guyatt G.H., et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care. N Engl J Med 330 6 (1994) 377-381
70. Kahn J.M., Doctor J.N., and Rubenfeld G.D. Stress ulcer prophylaxis in mechanically ventilated patients: integrating evidence and judgment using a decision analysis. Intensive Care Med 32 (2006) 1151-1158
71. Metheny N.A., Clouse R.E., Chang Y.H., et al. Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit Care Med 34 4 (2006) 1007-1015
72. Rivers E.P., Kruse J.A., Jacobsen G., et al. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit Care Med 35 9 (2007) 2016-2024
73. Shapiro N.I., Trzeciak S., Hollander J.E., et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 37 1 (2009) 1-9
74. Nobre V., Harbarth S., Graf J.D., et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177 5 (2008) 498-505
75. Castelli G.P., Pognani C., Meisner M., et al. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 8 4 (2004) R234-R242
76. Thiel S.W., Asghar M.F., Micek S.T., et al. Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med 37 3 (2009) 819-824
77. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49 2 (2005) 760-766
78. Khatib R., Saeed S., Sharma M., et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 25 3 (2006) 181-185
79. Schramm G.E., Johnson J.A., Doherty J.A., et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 34 8 (2006) 2239-2241
80. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 1 (2006) 25-31
81. Tumbarello M., Sanguinetti M., Montuori E., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51 6 (2007) 1987-1994
82. Cheong H.S., Kang C.I., Wi Y.M., et al. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis 27 12 (2008) 1219-1225